Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
Belimumab is approved for the treatment of active systemic lupus erythematosus. BASE was a double-blind, randomised, placebo-controlled, phase 4 trial...
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study
Juvenile idiopathic arthritis (JIA) is a heterogeneous disease. Clusters of children and young people might experience different global patterns in th...
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Tyrosine kinase 2 (TYK2) signaling has previously shown therapeutic potential in the treatment of psoriasis. The primary objective of this study was t...
68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study
Lung disease is the most common cause of death in systemic sclerosis. It is judged by the accrual of lung damage on CT and pulmonary function tests. T...
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study
Extracellular matrix remodeling is a hallmark of systemic sclerosis. Matrix neo-epitopes could be used in clinical practice to risk-stratify patients...
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key mediator of signs and symptoms in osteoarthritis. We explored the efficacy, safety,...
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
Activation of the type I interferon (IFN) pathway is associated with systemic lupus erythematosus (SLE) We assessed the safety and tolerability of JNJ...
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor. It has been proposed to mitigate the cytokine storm syndrome associa...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
